SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

H.C. Wainwright initiates Autolus Therapeutics coverage with Buy rating

H.C. Wainwright initiates coverage of Autolus Therapeutics with a Buy rating and a $10 price target.

AUTL
SquawkNews Desk 1 updates Updated Nov 02, 2026, 11:50 AM UTC

Story updates

11:50:40 AM UTC
SquawkNews
HC Wainwright & Co. assumes coverage of Autolus Therapeutics at Buy, sets price target at $10

Related stories

Fox Reports Higher Q1 FY27 EPS and Revenue Fox reported year-over-year increases in Q1 FY27 earnings per share and revenue. M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million An IDEXX executive said Covet revenue is growing at strong double-digit rates. M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC Infineon and Qualcomm Technologies Sign Automated Driving Agreement M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC Fox Shares Rise After Q1 Results Top Estimates Fox shares rise after first-quarter results top estimates, supported by advertising. M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC AAR Proposes $955 Million and $960 Million Senior Note Offerings AAR proposed $955 million of senior notes due 2031 and $960 million of senior notes due 2034. M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC Teva shares fall after rare brain disorder drug trial halted US-listed shares of Israel-based Teva fell after a trial of a drug for a rare brain disorder was halted. M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC